Evidence map›Paper›PMID 29553868›Full record

ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2018

Association Between Fibroblast Growth Factor Receptor 1 Gene Amplification and Human Papillomavirus Prevalence in Tonsillar Squamous Cell Carcinoma With Clinicopathologic Analysis.

Soonchan Park, Miji Lee, Kyung-Ja Cho, Sung Bae Kim, Jong-Lyel Roh, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Joon Seon Song

Open access · bronzeAbstract read
In one paragraph

Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Soonchan ParkDepartment of Radiology, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.
Miji LeeDepartment of Pathology, Veterans Health Service Medical Center, Seoul, Republic of Korea.
Kyung-Ja ChoDepartments of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Sung Bae KimMedical Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Jong-Lyel RohHead and Neck Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Seung-Ho ChoiHead and Neck Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Soon Yuhl NamHead and Neck Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Sang Yoon KimHead and Neck Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Joon Seon SongDepartments of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Ulsan College · KRAsan Medical Center · KRKyung Hee University Hospital at Gangdong · KRUniversity of Ulsan · KRVeterans Health Service Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplification of fibroblast growth factor receptor 1 ( FGFR1) has been reported in many squamous cell carcinomas, and human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma has been characterized as a distinct subset with favorable prognosis. Here, we investigated the FGFR1 amplification and HPV status in tonsillar squamous cell carcinoma (TSCC) and analyzed the clinical characteristics. HPV in situ hybridization (HPV ISH) and FGFR1 fluorescence in situ hybridization (FISH) were performed using tissue microarray from 89 cases of TSCC. Fourteen of 89 (15.7%) TSCC cases had FGFR1 amplification, and HPV was detected in 59 of 89 (66.3%) cases. FGFR1 amplification status was not associated with HPV positivity ( p=0.765). Outcomes were not significantly different between FGFR1 amplified and non-amplified patients. Although FGFR1 amplified patients ( n=4) in the HPV ISH-negative group ( n=30) had a tendency for poorer overall survival, no statistical significance was identified ( p=0.150, log-rank). FGFR1 protein overexpression showed better disease-free survival ( p=0.031, log-rank) in HPV-negative TSCC. This study suggests FGFR1 amplification may be important in the pathogenesis of TSCC regardless of HPV status.

Indexed as

AdultCarcinoma, Squamous CellDisease-Free SurvivalFemaleGene AmplificationHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateMaleMiddle AgedPalatine TonsilPapillomaviridaePapillomavirus InfectionsPrevalenceReceptor, Fibroblast Growth Factor, Type 1FGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1fibroblast growth factor receptor 1fluorescence in situ hybridizationhuman papillomavirussquamous cell carcinomatonsil

Identifiers

PMID29553868
PMCPMC6055260
OpenAlexW2793412961

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.